{"id":598542,"date":"2022-05-04T10:52:01","date_gmt":"2022-05-04T10:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=598542"},"modified":"2022-05-04T10:52:01","modified_gmt":"2022-05-04T10:52:01","slug":"cutaneous-tcell-lymphoma-market-size-epidemiology-pipeline-therapies-treatment-and-companies-by-delveinsight-celgene-galderma-innate-pharma-eisai-inc-novartis-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-tcell-lymphoma-market-size-epidemiology-pipeline-therapies-treatment-and-companies-by-delveinsight-celgene-galderma-innate-pharma-eisai-inc-novartis-and-others_598542.html","title":{"rendered":"Cutaneous T-Cell lymphoma Market Size, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight | Celgene, Galderma, Innate Pharma, Eisai Inc., Novartis and Others."},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1651638968.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cutaneous T-Cell lymphoma Market Size, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight | Celgene, Galderma, Innate Pharma, Eisai Inc., Novartis and Others.\" src=\"https:\/\/www.abnewswire.com\/uploads\/1651638968.jpeg\" alt=\"Cutaneous T-Cell lymphoma Market Size, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight | Celgene, Galderma, Innate Pharma, Eisai Inc., Novartis and Others.\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Cutaneous T-Cell lymphoma Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Cutaneous T-cell lymphoma<\/strong> (CTCL) is a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors; this group consist of the most common types of skin lymphoma. Furthermore, more than 3 out of every 4 skin lymphomas diagnosed are CTCLs and often appear as eczema-like skin rashes and can affect widespread parts of the body.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Cutaneous T-Cell Lymphoma Market<\/strong><\/a><strong> Insights, Epidemiology, and Market Forecast-2030&#8243;<\/strong>&nbsp;report delivers an in-depth understanding of the Cutaneous T-Cell Lymphoma(CTCL), historical and forecasted epidemiology as well as the Cutaneous T-Cell Lymphoma (CTCL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of the <\/strong><strong>CTCL Market<\/strong><strong> Report are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><em>The CTCL therapeutic market in the seven major markets was found to be USD 488.77 million in 2018 and is expected to increase during the forecast period.<\/em><\/li>\n<li><em>As per Delveinsight&rsquo;s estimates, the total incident population of cutaneous T-cell lymphomas in the 7MM was 7,447 in 2018.<\/em><\/li>\n<li><em>According to Delveinsight&rsquo;s estimates, the highest incident cases of this disease were observed in the United States, which accounted for approximately 44.83% of the total incident cases.<\/em><\/li>\n<li><em>Japan had 1,267 cases in 2018, which accounted for approximately 17% of the total 7MM incident cases of CTCL.<\/em><\/li>\n<li><em>In 2018, there were 1,778 male and 1,571 female incident cases of CTCL estimated in the United States.<\/em><\/li>\n<li><em>SGX301 (Soligenix), Tislelizumab (BeiGene) Cobomarsen (miRagen Therapeutics, Inc.), Resminostat (4SC), and E777 (Eisai) are the other drugs in the pipeline. SGX301 and E777 have also received Orphan Designation from the FDA.<\/em><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/a013406da646826ab9954c4e6d37de8b.jpg\" alt=\"\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request For Sample Page: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>&#8220;Cutaneous T-cell Lymphoma (CTCL) market share in 2017 was the highest for&nbsp;the United States&nbsp;followed by EU5 (Germany,&nbsp;France,&nbsp;Italy,&nbsp;Spain&nbsp;&amp; UK) and&nbsp;Japan.&#8221;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Cutaneous T-Cell Lymphoma<\/strong><strong> treatment<\/strong><\/a> depends on the disease stage. Early stage therapies are topical, including corticosteroids, retinoids, imiquimod (Aldara), ultraviolet A irradiation (PUVA), and total skin electron beam therapy. Systemic therapies are introduced in the advanced stages where the disease is widespread and\/or resistant to topical treatment. These include interferon alpha injections, stem cell transplant, alemtuzumab (MabCampath) and other chemotherapy regimens. The FDA approved drugs include Istodax (romidepsin), Valchlor (mechlorethamine), Uvadex (methoxsalen), Targretin (bexarotene) and Zolinza (vorinostat).<\/p>\n<p style=\"text-align: justify;\">A myriad of scheduled launches of emerging therapies within the forecast period (2018-30) is expected to change the dynamics of the CTCL market. The speculation garnered on the basis of the positive results exhibited by the ongoing clinical trials with respect to the drugs under development.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <\/strong><strong>CTCL Companies<\/strong><strong> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Celgene<\/li>\n<li>Galderma<\/li>\n<li>Innate Pharma<\/li>\n<li>Eisai Inc.<\/li>\n<li>Novartis Pharmaceuticals<\/li>\n<li>Soligenix<\/li>\n<li>Onxeo<\/li>\n<li>BioCryst Pharmaceuticals<\/li>\n<li>miRagen Therapeutics<\/li>\n<li>MedC Biopharma Corporation<\/li>\n<li>And many others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Cutaneous T-Cell Lymphoma <\/strong><strong>Therapies<\/strong><\/a><strong> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>SGX301<\/li>\n<li>Remetinostat<\/li>\n<li>AFM13<\/li>\n<li>Cobomarsen<\/li>\n<li>Resminostat<\/li>\n<li>Pembrolizumab<\/li>\n<li>E7777<\/li>\n<li>CD11301<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request For Sample Page: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Topics Covered<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Cutaneous T- Cell Lymphoma (CTCL) Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">3. Cutaneous T- Cell Lymphoma (CTCL) Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">4. Cutaneous T- Cell Lymphoma (CTCL) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">5. Cutaneous T- Cell Lymphoma (CTCL) Incident Population in 7MM<\/p>\n<p style=\"text-align: justify;\">6. Cutaneous T- Cell Lymphoma (CTCL) Country Wise-Epidemiology<\/p>\n<p style=\"text-align: justify;\">7. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">8. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">9. Cutaneous T- Cell Lymphoma (CTCL) Marketed Drugs<\/p>\n<p style=\"text-align: justify;\">10. Cutaneous T- Cell Lymphoma (CTCL) Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">11. Cutaneous T- Cell Lymphoma (CTCL) 7 Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">12. The United States Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. EU-5 Countries: Market Outlook<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers<\/p>\n<p style=\"text-align: justify;\">15. Market Barriers<\/p>\n<p style=\"text-align: justify;\">16. Appendix<\/p>\n<p style=\"text-align: justify;\">17. Report Methodology<\/p>\n<p style=\"text-align: justify;\">18. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">19. Disclaimer<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cutaneous-tcell-lymphoma-market-size-epidemiology-pipeline-therapies-treatment-and-companies-by-delveinsight-celgene-galderma-innate-pharma-eisai-inc-novartis-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cutaneous-tcell-lymphoma-market-size-epidemiology-pipeline-therapies-treatment-and-companies-by-delveinsight-celgene-galderma-innate-pharma-eisai-inc-novartis-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cutaneous T-Cell lymphoma Market Cutaneous T-cell lymphoma (CTCL) is a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors; this group consist of the most common &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-tcell-lymphoma-market-size-epidemiology-pipeline-therapies-treatment-and-companies-by-delveinsight-celgene-galderma-innate-pharma-eisai-inc-novartis-and-others_598542.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-598542","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/598542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=598542"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/598542\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=598542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=598542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=598542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}